Lupin Limited (LUPIN)
🎯 Key Takeaways
- Lupin Limited is in a strategic transition phase, actively reshaping its portfolio by exiting direct oncology development through the acquisition of an 82.2% stake in Kaveri Therapeutics Inc.
- Revenue grew 1.7% QoQ to ₹5,768 in Q3FY25.
- ⚠️ Execution risk in achieving ESG targets, particularly in water-stressed regions and supply chain decarbonization, which could impact operational costs
📖 The Story
Lupin Limited is in a strategic transition phase, actively reshaping its portfolio by exiting direct oncology development through the acquisition of an 82.2% stake in Kaveri Therapeutics Inc. This move allows the company to offload underperforming programs (LNP7457 and LNP8701) while leveraging external leadership for accelerated advancement. Concurrently, Lupin is reinforcing its sustainability commitments and operational efficiency, as reflected in its ESG reporting and incremental capital actions. The company is balancing growth in core businesses with disciplined capital allocation amid evolving market dynamics in the pharmaceutical sector.
📰 What's Happening
In July 2026, Lupin completed the acquisition of an 82.2% stake in Kaveri Therapeutics Inc. for USD 1.6 million, licensing out its two oncology programs to accelerate development under Kaveri's leadership. This strategic exit from direct oncology development was formally announced in a BSE filing on July 21, 2026. Additionally, on July 8, 2026, the company allotted 2,358 equity shares under employee stock options, increasing its paid-up capital. The 44th AGM is scheduled for August 4, 2026, where a final dividend of ₹18 per share is proposed, subject to shareholder approval. These actions underscore a focus on portfolio optimization and shareholder returns.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 |
| Operating Profit | 615 | 879 | 958 | 1,067 | 1,026 | 1,309 | 1,383 | 1,410 |
| OPM % | 13.0% | 17.8% | 18.2% | 20.0% | 20.1% | 22.2% | 23.6% | 23.5% |
| Net Profit | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 |
| EPS | ₹5.19 | ₹9.94 | ₹10.76 | ₹13.47 | ₹7.89 | ₹17.58 | ₹18.70 | ₹18.75 |
Lupin has demonstrated consistent top-line growth and margin expansion over the past four quarters, with revenue rising from ₹4,430 crore in Q4FY23 to ₹5,768 crore in Q3FY25, accompanied by a corresponding improvement in operating profit margin from 13.0% to 23.5%. Net profit has grown steadily from ₹242 crore to ₹859 crore over the same period, reflecting operational efficiency and scale benefits. The sequential improvement in profitability aligns with management's focus on cost discipline and product mix optimization, although growth remains incremental rather than transformative. The upward trend in EPS, from ₹5.19 to ₹18.75 over two years, indicates strengthening bottom-line performance.
🔮 Management Outlook & What's Next
In its Sustainability Report 2025-26 filed on July 13, 2026, management outlined ambitious environmental targets, including a 42% absolute reduction in Scope 1 and 2 emissions by 2030 from a FY23 baseline and a 61% Scope 3 intensity reduction by 2034. Social goals include achieving 35% renewable electricity usage by 2030 and 10% fresh water withdrawal reduction by the same year. Governance disclosures reaffirm board oversight via the Sustainability & CSR Committee and DNV-verified assurance. Management emphasized progress on climate action and patient access programs, with no formal financial guidance provided but clear long-term ESG milestones tied to operational execution.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in achieving ESG targets, particularly in water-stressed regions and supply chain decarbonization, which could impact operational costs and regulatory compliance. 2. Integration risk associated with the Kaveri Therapeutics acquisition, where the success of oncology program advancement depends on external management performance. 3. Margin pressure from pricing competition in generic markets, despite current OPM expansion, as global tenders and procurement pressures persist. 4. Dependence on a limited number of high-margin products, with growth in core businesses needing to offset margin compression in commoditized segments.
📋 Recent Filings
-
Announcement 31 July 2026Lupin Limited announced FDA approval for its generic Diazepam Injection USP in the United States, targeting the $77.9 million annual market for anxiet...
-
Announcement 22 July 2026Lupin Limited announced its Q1 FY27 earnings call scheduled for August 7, 2026 at 16:30 IST, inviting investors to register via Zoom, as disclosed in ...
-
🔴 Announcement 21 July 2026Lupin announced the completion of its acquisition of an 82.2% stake in newly formed Kaveri Therapeutics Inc. through a licensing deal for two oncology...
-
Announcement 14 July 2026Lupin Limited announced it has been recognized as one of India's Best Employers in the Nation Builders category by Great Place To Work India 2026, ran...
-
🟡 sustainability report 13 July 2026Lupin Limited's Business Responsibility and Sustainability Report 2025-26, filed on July 13, 2026, details its ESG performance across environmental, s...
-
🔴 Corporate Action 8 July 2026Lupin announced its 44th AGM on August 4, 2026, and set July 17, 2026 as the record date for a proposed final dividend of ₹18 per share on the March 3...
-
🔴 Corporate Action 8 July 2026Lupin Limited announced on July 8, 2026 that its Operations and Finance Committee allotted 2,358 fully paid-up equity shares of ₹2 each by exercising ...
-
🟡 Board Meeting 8 July 2026Lupin Limited announced its 44th Annual General Meeting scheduled for August 4, 2026, where shareholders will vote on a proposed final dividend of ₹18...
-
Announcement 6 July 2026Lupin Limited announced its inclusion in TIME and Statista's World's Most Sustainable Companies 2026 list, ranking 318th out of 750 globally and among...
-
Announcement 1 July 2026Lupin announced EMA approval for NaMuscla's expanded pediatric indication covering children aged 6-11 with non-dystrophic myotonic disorders, adding 6...
🧠 Analyst's Read
Lupin is transitioning from a pure-play generic manufacturer to a more diversified entity with emerging sustainability credentials and a streamlined oncology portfolio strategy. The company's financial trajectory shows steady improvement, but growth remains modest, and long-term value hinges on ESG execution and successful outsourcing of oncology development. Investors should monitor progress on emission reduction targets, dividend sustainability, and the commercial trajectory of Kaveri-led programs as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LUPIN files new disclosures
Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LUPIN — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research